TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1467127
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low protein diet (0.4 g of protein/kg b.w./day) supplemented with essential amino acids
Study: 1467127
Drug: Conventional low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional low protein diet (0.6 g of protein/kg b.w./day)
Study: 19254671
Drug: Pyridostigmine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (45 mg, 3 times/day, for 24 hours)
Study: 11750185
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of d-amphetamine
Study: 9439150
Drug: Levamisole added
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole added to chemotherapy (5-fluorouracil 1,000 mg/m2/day for 5 days and cisplatin 60 mg/m2 for 1 day)
Study: 9439150
Drug: Non-levamisole group
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-levamisole group (5-fluorouracil 1,000 mg/m2/day for 5 days and cisplatin 60 mg/m2 for 1 day)
Study: 9439150
Drug: Levamisole added
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole added to chemotherapy
Study: 8507222
Drug: Aspirin in
Normalized name: Non-Aspirin Infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin in RA patients
Study: 8507222
Drug: Aspirin in
Normalized name: Non-Aspirin Infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin in OA patients
Study: 3565302
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g xylitol
Study: 24764677
Drug: Resistance Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance Training (RT) - 3 times weekly for 3 months, including exercises like leg press, chest press, seated rowing, latissimus pull down, with 8-12 repetitions, 3 sets for each exercise, total duration of 40 min.
Study: 20101197
Drug: Continuous heparin
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous heparin at 10 units/kg/hr
Study: 20101197
Drug: Continuous heparin
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous heparin at 10 units/kg/hr (aged <30 days)
Study: 16000966
Drug: REST routine
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: REST routine treatment group
Study: 10759091
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 to 400 mg/day)
Study: 8828525
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of H1-receptor antagonist (azelastine)
Study: 1520649
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion at 9.25 micrograms/kg/min over 24 hours
Study: 26986995
Drug: Gentamicin 5
Normalized name: gentamicin 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 5 mg kg(‐1) intravenous (i.v.) every 36 h
Study: 26986995
Drug: Traditional dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional dosage of gentamicin
Study: 23427280
Drug: Ranolazine 375
Normalized name: Ranolazine 375 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 375 mg twice daily orally plus intravenous amiodarone
Study: 23427280
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone alone
Study: 22993421
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of MPH
Study: 10454703
Drug: Maternal intravenous
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal intravenous infusion of amino acids (Freamine 8.5% III, Baxter)
Study: 2316590
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg) every 4 hours
Study: 6299842
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage vaccine
Study: 6299842
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage vaccine
Study: 21654314
Drug: Enzastaurin (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (loading dose of 500 mg, followed by 250 mg daily) and Sunitinib (50 mg/d for 4 weeks)
Study: 21654314
Drug: Enzastaurin (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (loading dose of 1125 mg, followed by 500 mg daily) and Sunitinib (50 mg/d for 4 weeks)
Study: 19327620
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of isosorbide dinitrates and hydralazine (FDC I/H)
Study: 17533403
Drug: PVACEBOP multi-agent
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVACEBOP multi-agent chemotherapy as primary therapy for high-risk patients (SNLG index >or=0.5)
Study: 17533403
Drug: Standard ChlVPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ChlVPP or ABVD chemotherapy+/−radiotherapy for standard risk patients (SNLG index <0.5)
Study: 17533403
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (salvage therapy)
Study: 16447051
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone once daily for 5 days
Study: 14631456
Drug: Diazepam, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam, 15 mg
Study: 1503435
Drug: Intranasal pirodavir
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal pirodavir (2 mg per dose, 6 times per day for a total of 25 doses)
Study: 1503435
Drug: Intranasal pirodavir
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal pirodavir (2 mg per dose, 3 doses daily)
Study: 1503435
Drug: Intranasal pirodavir
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal pirodavir (24 h after RV challenge)
Study: 29135501
Drug: Control treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatments only
Study: 24030945
Drug: Kisspeptin-54 (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kisspeptin-54 (6.4 nmol/kg, twice-daily subcutaneous injections during menstrual days 7-14)
Study: 17805229
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (3 g day(-1), fish oil capsules)
Study: 17805229
Drug: Placebo (only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (only capsules)
Study: 10891632
Drug: Naltrexone/Lofexidine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone/Lofexidine combination treatment
Study: 10891632
Drug: Conventional Lofexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Lofexidine treatment
Study: 1893706
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl estradiol 35 ug plus norethindrone 0.4 mg
Study: 1893706
Drug: 30 ug
Normalized name: SUFENTANIL 30 ug SUBLINGUAL TABLET [Dsuvia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ug ethinyl estradiol plus 1.5 mg norethindrone acetate
Study: 1893706
Drug: spironolactone 200
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spironolactone 200 mg daily
Study: 1893706
Drug: ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ethinyl estradiol 30 ug plus 1.5 mg norethindrone acetate
Study: 6228504
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (comparison group)
Study: 24415559
Drug: Sacral neuromodulation
Normalized name: Boswellia sacra whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacral neuromodulation (SNM) with InterStim Therapy
Study: 24415559
Drug: Medication-related adverse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-related adverse events
Study: 24055014
Drug: IPX066 145
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX066 145 mg TID
Study: 24055014
Drug: IPX066 245
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX066 245 mg TID
Study: 24055014
Drug: IPX066 390
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX066 390 mg TID
Study: 20015903
Drug: Topical intranasal
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intranasal corticosteroids (Mometasone furoate 50 microg)
Study: 17538170
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (vinorelbine plus cisplatin)
Study: 9147422
Drug: Two-drug regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug regimen (clarithromycin 500 mg twice daily and ethambutol 800-1,000 mg daily)
Study: 9147422
Drug: Three-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimen (clarithromycin 500 mg twice daily, ethambutol 800-1,000 mg daily, and clofazimine 100 mg daily)
Study: 2881786
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (0.1-0.2 microgram kg-1 min-1)
Study: 2881786
Drug: Pindolol (beta-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (beta-adrenergic blocker)
Study: 2881786
Drug: Practolol (beta-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (beta-adrenergic blocker)
Study: 30223721
Drug: Hypoglossal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglossal nerve stimulation therapy
Study: 27504914
Drug: adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab 40 mg every-other-week (following a single 80 mg dose)
Study: 19404392
Drug: Daily acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily acyclovir for genital herpes (HSV-2) suppression
Study: 15383110
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (diamorphine 1.2 mg loading dose intravenously)
Study: 15383110
Drug: Intramuscular diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diamorphine (as per hospital protocol)
Study: 11149996
Drug: Grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass pollen immunotherapy (n = 22)
Study: 2407813
Drug: Adjuvant single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant single-agent chemotherapy with doxorubicin
Study: 7001863
Drug: Thiazide diuretics
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretics (bendroflumethiazide, chlorthalidone, hydrochlorothiazide)
Study: 7001863
Drug: Loop diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics (bumetanide, furosemide, triamterene)
Study: 25791173
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant (Tisseel) applied to the uterine cervix (2 ml)
Study: 20801938
Drug: Riociguat (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (2.5 mg, 3 times daily for 10 days)
Study: 20801938
Drug: Warfarin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (25 mg single oral dose)
Study: 17138821
Drug: Standard intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intensity FAB/LMB therapy
Study: 17138821
Drug: Reduced intensity
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced intensity therapy (reduced cytarabine plus etoposide and deletion of 3 maintenance courses M2, M3, M4)
Study: 17138821
Drug: Combined BM/CNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined BM/CNS disease at diagnosis or poor response to COP reduction therapy
Study: 10872909
Drug: 5-fluorouracil (1%)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (1%) in vaginal hydrophilic gel
Study: 3743860
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with hydralazine and pindolol
Study: 27955663
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFA) 3g daily for 24 weeks
Study: 15792398
Drug: Ibuprofen sodium
Normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen sodium dihydrate (2 x 200 mg t.i.d.)
Study: 15792398
Drug: Ibuprofen sodium
Normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen sodium dihydrate
Study: 15792398
Drug: Ibuprofen arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen arginate (2 x 200 mg t.i.d.)
Study: 12787013
Drug: Scalp cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp cooling via gel cool caps
Study: 10984365
Drug: Fluticasone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (100 microg twice daily) for 7 days
Study: 10984365
Drug: Fluticasone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (100 microg twice daily) for 7 days in children with rhinovirus infection
Study: 6486559
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of slow-release theophylline (TheoDur) twice a day
Study: 30270639
Drug: Acetaminophen (ACT)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (ACT) 1 g
Study: 27404031
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (1 mg/d, n=22)
Study: 24874565
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g oat bran
Study: 24874565
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g barley bran
Study: 21095280
Drug: Eplerenone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (50 mg/d)
Study: 18211446
Drug: Lidocaine (analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (analgesic concentration)
Study: 18211446
Drug: Levobupivacaine (analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (analgesic concentration)
Study: 18211446
Drug: Ropivacaine (analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (analgesic concentration)
Study: 10781471
Drug: Midazolam plus
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam plus fentanyl (0.03 mg/kg plus 2 microg/kg)
Study: 1621247
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg d-indobufen
Study: 1621247
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dl-indobufen
Study: 3883734
Drug: Molsidomine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (2 mg oral dose)
Study: 30404622
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC) in the active pill phase (20th to 21st day of OC cycle)
Study: 30404622
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OC) in the inactive pill phase (2nd to 4th day of OC cycle)
Study: 27287206
Drug: PEG‐IFN (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN (180 μg subcutaneously 1×/week; 24 months)
Study: 24135621
Drug: Spa treatment
Normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa treatment (balneotherapy) for 3 weeks, consisting of four sessions per day for 6 days a week.
Study: 24135621
Drug: Spa treatment
Normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa treatment (balneotherapy) for 3 weeks.
Study: 24135621
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received spa treatment after 1 year.
Study: 12479668
Drug: Oral loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loading dose of valproate (20 mg/kg/day)
Study: 12479668
Drug: Slower titration
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slower titration dose of valproate (10 mg/kg/day)
Study: 2697568
Drug: Pharmaceutical industry
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical industry involvement
Study: 21353372
Drug: MVI 50
Normalized name: alpha-tocopherol acetate / ascorbic acid / biotin / dexpanthenol / ergocalciferol / folic acid / niacinamide / pyridoxine hydrochloride / riboflavin / thiamine hydrochloride / vitamin A / vitamin B12 / vitamin K1 Injectable Solution [MVI Pediatric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVI 50 (misoprostol 50 mcg)
Study: 18582848
Drug: Memantine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (maximum dose 20 mg/day)
Study: 26066335
Drug: Curcumin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1000 mg daily for 6 weeks)
Study: 24476477
Drug: Curcumin 50
Normalized name: curcumin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 50 mg/kg daily for 8 weeks in DM
Study: 24476477
Drug: Curcumin 500
Normalized name: curcumin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 500 mg daily for 12 weeks in obese humans
Study: 24476477
Drug: Curcumin 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 750 mg daily for 12 weeks in obese humans
Study: 19364302
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg once daily
Study: 19364302
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg once daily plus Metformin 1000 mg once daily
Study: 4028807
Drug: Slow-release tablet
Normalized name: Focalgin DSS 90mg Slow-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release tablet formulation of 300 mg fentiazac, given once daily
Study: 4028807
Drug: Standard tablet
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tablet formulations of 100 mg, given 4-times daily
Study: 4028807
Drug: Standard tablet
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tablet formulations of 200 mg, given twice daily
Study: 24475777
Drug: Fingolimod 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 1.25 mg or 0.5 mg (switched from placebo)
Study: 24475777
Drug: Fingolimod (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (in AQP4 antibody-positive patients)
Study: 22268125
Drug: Protandim (1,350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protandim (1,350 mg/day)
Study: 20852750
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg tablet; LPH® S.C. LaborMed Pharma S.A. Romania)
Study: 20852750
Drug: Zantac® (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zantac® (300 mg tablet; GlaxoSmithKline, Austria)
Study: 18180567
Drug: Hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G-F 20 (Synvisc, n=18)
Study: 16303007
Drug: Fluvastatin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin XL 80 mg/day
Study: 31455707
Drug: Soft tissue
Normalized name: INSULIN DETEMIR 14.2 mg in 1 mL SOFT TISSUE IMPLANT [Levemir]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft tissue therapy (70%)
Study: 25967725
Drug: Low-dose selective
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose selective spinal anesthesia with 5 mg bupivacaine + single‐shot femoral block with 0.25% bupivacaine
Study: 25967725
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose selective spinal anesthesia with 10 mg bupivacaine
Study: 24045793
Drug: 10 different
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 different food ingredients (including coffee, tea, milk, curcumin, potato protease inhibitor)
Study: 21863030
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (320 mg day(-1))
Study: 19549707
Drug: CET-CF (cetuximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: CET-CF (cetuximab plus cisplatin-5-fluorouracil); cetuximab 400 mg/m² initial dose followed by 250 mg/m² weekly, cisplatin 100 mg/m² on day 1, 5-FU 1000 mg/m² days 1-5 for a maximum of six 29-day cycles.
Study: 19549707
Drug: CF (cisplatin-5-fluorouracil);
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF (cisplatin-5-fluorouracil); cisplatin 100 mg/m² on day 1, 5-FU 1000 mg/m² days 1-5 for a maximum of six 29-day cycles.
Study: 14715393
Drug: Paracetamol 600/650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 600/650 mg
Study: 11887670
Drug: Dental appliance
Normalized name: Efferdent Anti-Bacterial Dental Appliance Cleanser Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental appliance treatment for headache patients
Study: 20643762
Drug: Infliximab combined
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab combined with oral CYC
Study: 20643762
Drug: Other agents
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other agents including biological agents
Study: 12946761
Drug: Intracorporeal injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracorporeal injection
Study: 8899091
Drug: Low-dose rINF-beta
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rINF-beta ser (6 x 10(6) U/dose, three times a week for 6 months)
Study: 8899091
Drug: High-dose rINF-beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rINF-beta ser (30 x 10(6) U/dose, three times a week for 6 months)